Aktis Oncology raised $175M in a Series B round led by RA Capital Management to advance its pipeline of targeted alpha radiopharmaceuticals.
Amount Raised
$175 Million
Round Type
Series B
BostonBiotechnologyHealth CareTherapeuticsInvestors
Description
Aktis Oncology, a clinical-stage biotechnology company based in Boston, secured $175 million in a Series B financing round. The funding will be utilized to further advance its differentiated radiopharmaceuticals pipeline, focusing on Nectin-4-targeted therapies.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Aktis Oncology that raised within 45 days of this round, from Fundz verified event records.
- TRex Bio raised $84M (Series B) on November 13, 2024.
- Phlox Therapeutics raised $2M (Seed) on November 13, 2024.
- Hyku Biosciences raised $64M (Seed) on November 12, 2024.
- Zucara Therapeutics raised $20M (Series B) on November 12, 2024.
- Strata Oncology raised $6.1M on November 8, 2024.
- TRex Bio raised $42M on November 7, 2024.
Who to call at Aktis Oncology, and when
A new round usually means Aktis Oncology is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Aktis Oncology raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Aktis Oncology, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Aktis Oncology. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Aktis Oncology raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAktis Oncology raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.